Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2000, p. 3663-3669, Vol. 38, No. 10
Respiratory Diseases Branch, Centers for
Disease Control and Prevention, Atlanta, Georgia
30333,1 and Department of
Microbiology, University of Alabama at Birmingham, Birmingham, Alabama
352052
Received 26 April 2000/Returned for modification 1 July
2000/Accepted 1 August 2000
In a recent genotypic survey of
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Pneumococcal pspA Sequence Types of
Prevalent Multiresistant Pneumococcal Strains in the United States and
of Internationally Disseminated Clones

-lactam-resistant pneumococci
recovered in different areas of United States during 1997, eight clonal
types that each represented 3 to 40 isolates accounted for 134 of 144 isolates (G. Gherardi, C. Whitney, R. Facklam, and B. Beall, J. Infect. Dis. 181:216-229, 2000). We determined the degree of
pspA gene diversity among these 134 isolates and for 11 previously characterized internationally disseminated multiresistant strains. Thirty-four different pspA restriction profiles
were determined for an amplicon encompassing the variable portion of the structural gene that encodes the surface-exposed domain of PspA and
a variable-length proline-rich putative cell wall-associated domain.
These restriction profiles closely correlated with those of 33 different pspA sequence types of an approximately
230-residue region corresponding to residues 182 to 410 of the strain
Rx1 PspA. These residues encompass a 100-residue clade-defining region known to contain cross-protective epitopes for which 17 sequence types were found. Distinct, conserved pspA sequence types
were found for the majority of strains within seven of the eight U.S. clonal types assessed, while one pulsed-field gel electrophoresis type
was represented by isolates of three distinct PspA clades. Sequence
typing of pspA provides an added level of specificity in
the subtyping of isolates and is a necessary first step in determining
the components needed in a PspA vaccine which could elicit effective
cross-protective coverage.
*
Corresponding author. Mailing address: Centers for
Disease Control and Prevention, Mailstop C02, 1600 Clifton Rd., NE,
Atlanta, GA 30333. Phone: (404) 639-1237. Fax: (404) 639-3123. E-mail: beb0{at}cdc.gov.
Present address: Libera Università Campus Bio-Medico, 00155, Rome, Italy.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|